{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:08:08Z","timestamp":1771927688848,"version":"3.50.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Circulating tumor DNA (ctDNA) has demonstrated a strong predictive capacity for recurrence in early-stage breast cancer compared with imaging examinations. However, there remains a paucity of robust clinical evidence to guide the adjustment of adjuvant therapy based on minimal residual disease (MRD) status in early-stage breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 69-year-old female patient with early-stage triple-negative breast cancer (TNBC) with somatic BRCA2 mutations exhibited an exceptional response to adjuvant therapy with olaparib. Personalized ctDNA monitoring, utilizing a tumor-informed approach, was employed alongside imaging examinations and tumor biomarker testing to monitor tumor recurrence. MRD positivity was detected at four months and approximately one-month post-treatment discontinuation. Resumption of olaparib therapy resulted in a negative MRD status, while imaging examinations consistently demonstrated no evidence of recurrence in the patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This report underscores the potential benefit of olaparib for early-stage TNBC patients with somatic BRCA2 mutations and the utility of serial ctDNA monitoring for tailoring individualized treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1679086","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T06:45:50Z","timestamp":1769582750000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Individualized circulating tumor DNA monitoring guides olaparib adjuvant therapy: an early-stage breast cancer case with somatic BRCA2 mutation"],"prefix":"10.3389","volume":"16","author":[{"given":"Qiuting","family":"You","sequence":"first","affiliation":[{"name":"Breast Tumor Center, S\u2019 Clinic","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longlong","family":"Gong","sequence":"additional","affiliation":[{"name":"Genecast Biotechnology Co., Ltd","place":["Wuxi, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[{"name":"Breast Tumor Center, S\u2019 Clinic","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxiao","family":"Dinglin","sequence":"additional","affiliation":[{"name":"Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziliang","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Xia","sequence":"additional","affiliation":[{"name":"Breast Tumor Center, S\u2019 Clinic","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinxia","family":"Xie","sequence":"additional","affiliation":[{"name":"Breast Tumor Center, S\u2019 Clinic","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianli","family":"Zhao","sequence":"additional","affiliation":[{"name":"Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengxi","family":"Su","sequence":"additional","affiliation":[{"name":"Breast Tumor Center, S\u2019 Clinic","place":["Guangzhou, China"]},{"name":"Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34809","article-title":"Global burden of 34 cancers among women in 2020 and projections to 2040: Population-based data from 185 countries\/territories","volume":"154","author":"Bizuayehu","year":"2024","journal-title":"Int J Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: Global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13958","article-title":"Incidence, mortality, survival, and disease burden of breast cancer in China compared to other developed countries","volume":"19","author":"Tao","year":"2023","journal-title":"Asia Pac J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw027","article-title":"The global decrease in cancer mortality: trends and disparities","volume":"27","author":"Hashim","year":"2016","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602253","article-title":"70-gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"New Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-020-00482-7","article-title":"Oncotype DX breast recurrence score\u00ae: A review of its use in early-stage breast cancer","volume":"24","author":"Syed","year":"2020","journal-title":"Mol Diagnosis Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3663","article-title":"Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence","volume":"25","author":"Coombes","year":"2019","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3005","article-title":"Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer","volume":"26","author":"Parsons","year":"2020","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00908","article-title":"Circulating tumor DNA and late recurrence in high-risk hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer","volume":"40","author":"Lipsyc-Sharf","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1158\/1078-0432.CCR-23-2326","article-title":"Comparison of circulating tumor DNA assays for molecular residual disease detection in early-stage triple-negative breast cancer","volume":"30","author":"Coakley","year":"2024","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.23370","article-title":"Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial","volume":"325","author":"Wang","year":"2021","journal-title":"Jama"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2240","article-title":"Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY","volume":"35","author":"Kataoka","year":"2024","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"SESS","DOI":"10.1158\/1557-3265.SABCS24-GS3-01","article-title":"GS3-01: Circulating tumor DNA surveillance in ZEST, a randomized, phase 3, double-blind study of niraparib or placebo in patients w\/triple-negative breast cancer or HER2+ BRCA-mutated breast cancer with molecular residual disease after definitive therapy","author":"Turner","year":"2024","journal-title":"San Antonio Breast Cancer Symposium"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.03.180","article-title":"161O VIOLETTE: Randomised phase II study of olaparib (ola) + ceralasertib (cer) or adavosertib (ada) vs ola alone in patients (pts) with metastatic triple-negative breast cancer (mTNBC)","volume":"33","author":"Tutt","year":"2022","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad139","article-title":"Neoadjuvant talazoparib in patients with germline BRCA1\/2 mutation-positive, early-stage triple-negative breast cancer: results of a phase II study","volume":"28","author":"Litton","year":"2023","journal-title":"oncologist"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02151","article-title":"TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.annonc.2020.10.471","article-title":"Neoadjuvant paclitaxel\/olaparib in comparison to paclitaxel\/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)","volume":"32","author":"Fasching","year":"2021","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"154428","DOI":"10.1016\/j.prp.2023.154428","article-title":"Advances in the diagnosis and prognosis of minimal residual lesions of breast cancer","volume":"245","author":"Cui","year":"2023","journal-title":"Pathol - Res Pract"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16966","article-title":"Comprehensive landscape and interference of clonal haematopoiesis mutations for liquid biopsy: A Chinese pan-cancer cohort","volume":"25","author":"Xu","year":"2021","journal-title":"Journal of Cellular and Molecular Medicine"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1679086\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:15:02Z","timestamp":1771924502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1679086\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":26,"alternative-id":["10.3389\/fonc.2026.1679086"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1679086","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"article-number":"1679086"}}